Fusun Yildiz (Kocaeli, Turkey), Bilun Gemicioglu (Istanbul, Turkey), Tania Maes (Ghent, Belgium), Mohamed Al-Moamary (Riyadh, Saudi Arabia)
A weight-based exacerbation dose-response analysis of mepolizumab in severe asthma with eosinophilic phenotype
Isabelle Pouliquen (Uxbridge, United Kingdom), Isabelle Pouliquen, Daren Austin, Necdet Gunsoy, Steven Yancey
|   |
Reslizumab (RES) in asthma patients (pts) with severe eosinophilic asthma stratified by GINA asthma steps 4 and 5: Analysis of two phase 3, placebo (PBO)-controlled trials
Guy Brusselle (Ghent, Belgium), Guy Brusselle, Jennifer McElhattan, Janice Canvin, Roland Buhl
| |
SQ HDM SLIT-tablet is effective in patients not well-controlled in GINA treatment steps 2-4
Johann Christian Virchow (Rostock, Germany), Johann Christian Virchow, Victoria Cardona, Hanne Villesen, Christian Ljørring, Bente Riis, Frederic de Blay
| |
Fluticasone propionate/formoterol breath-triggered inhaler: Ease-of-use and patient preference
Mark Lomax (Cambridge, United Kingdom), David Bell, Lucielle Mansfield, Mark Lomax
| |
MiRNA-183 cluster in response to asthma treatment
Aleksandra Divac Rankov (Belgrade, Republic of Serbia), Sandra Dragicevic, Vanja Radulovic, Natasa Anastasov, Michael Atkinson, Dragica Radojkovic, Aleksandra Divac Rankov
| |
Evaluation method of airways for asthma patients using low dose HRCT images
Levent Kart (Istanbul, Turkey), Emine Doganay, Levent Kart, Hatice Kutbay Özçelik, Sadik Kara
| |
Vitamin D for the management of asthma: Cochrane systematic review and meta-analysis
Adrian R Martineau (London, United Kingdom), Adrian R. Martineau, Christopher J. Cates, Mitsuyoshi Urashima, Megan Jensen, Alex P. Griffiths, Ulugbek Nurmatov, Aziz Sheikh, Christopher J. Griffiths
| |
Effect of systemic inflammation and multi-morbidity on outcome of adult-onset asthma
Pinja Ilmarinen (Seinäjoki, Finland), Pinja Ilmarinen, Leena E. Tuomisto, Onni Niemelä, Joanna Danielsson, Jussi Haanpää, Terhi Kankaanranta, Hannu Kankaanranta
| |
Clinical evaluation of fluticasone/formoterol twice daily delivered via a single dose dry powder inhaler in patients with persistent asthma
Jaideep Gogtay (Mumbai, Maharashtra, India), Pradyut Waghray, Mahip Saluja, Mayank Agarwal, Abhijit Vaidya, Jaideep Gogtay, Ashish Kumar Deb, Sneha Limaye, Ashish Goyal, Aloke Gopal Ghoshal, Sudhir Bhatnagar, Akash Balki, George Dsouza, Manish Kumar Jain, Sharad Tikkiwal, Sujeet Rajan, Raja Dhar
| |
The ’real-life’ long-term efficacy of omalizumab in severe persistent IgE-mediated allergic asthma in Malta
Caroline Gouder (Kappara, Malta), Caroline Gouder, Rachelle Asciak, Stephen Montefort
| |
Effect of borago extract on moderate persistent asthma, a phase two randomized, double blind placebo-controlled clinical trial
Majid Mirsadraei (Mashhad, Islamic Republic of Iran), Majid Mirsadraee, Sara Khashkhashi Moghaddam, Parisa Saeidi
| |
Total and free IgE in evolution of severe asthma after omalizumab treatment
Ebymar Arismendi Nunez (Barcelona, Spain), María del Carmen Vennera, Mariona Pascal, Ebymar Arismendi Nunez, César Picado
| |
Fluticasone propionate/formoterol therapy for asthmatic patients: Results of a non-interventional study
Olaf Schmidt (Koblenz, Germany), Olaf Schmidt, Frank Kanniess, Petra Oepen, Birgit Langer-Brauburger
| |
Consumption of asthma and allergy drugs in Finland
Paula Kauppi (Helsinki, Finland), Paula Kauppi, Juha Jantunen, Jaana Martikainen, Mika Mäkelä, Tari Haahtela
| |
Efficacy of omalizumab in Polish real-world patients
Agnieszka Gawlewicz-Mroczka (Krakow, Poland), Agnieszka Gawlewicz-Mroczka, Weronika Zastrzezynska, Marek Przybyszowski, Adam Cmiel, Krzysztof Sladek
| |
Audit of bronchial thermoplasty patients who did not complete their treatment session as planned
LJ Holmes (Manchester, United Kingdom), K. Hince, L.J. Holmes, G. McCumesky, C. Ustabasi, R.M. Niven, D. Ryan
| |
P-PiXel: A ’real-life’ evaluation of omalizumab use in asthmatic patients
Antoine Poskin (Vilvoorde, Belgium), Alain Michils, Antoine Poskin, Jan Van Schoor, Stefaan Vancayzeele, Sandra Gurdain, Muriel Lins
| |
Effect of switching from salmeterol/fluticasone dry powder inhaler to formoterol/fluticasone pressurized metered-dose inhaler in elderly asthma patients
Hiroyuki Nagase (Tokyo, Japan), Hiroyuki Nagase, Naoya Sugimoto, Hidenori Arai, Hisanao Yoshihara, Michio Kuramochi, Mika Ohsumi, Yuta Koizumi, Yusuke Tanaka, Shoki Ro, Masao Yamaguchi, Ken Ohta
| |
A single-dose double-blind study comparing efficacy of two dry powder inhalers containing budesonide and formoterol in asthmatic patients
Satu Lahelma (Kuopio, Finland), Satu Lahelma, Mikko Vahteristo, Hristo Metev, Margarita Taseva, Nadezhda Stamatova, Anna Bartha, Judit Schlezák, Ulla Sairanen
| |
LATE-BREAKING ABSTRACT: Safety, pharmacokinetics and pharmacodynamics of BI 1060469, a novel oral CRTH2 antagonist
Eric Bateman (Cape Town, South Africa), Eric Bateman, Alison Mackie, Ewald Benediktus, Carnelia Schepers, Jiyeong Maria Kim, Yusuke Tadayasu, Ganghyuck Lee, Chester Wood
| |